Last updated: July 16, 2026
Adverio Pharma GmbH sued MSN Laboratories Private Limited under the Hatch-Waxman framework in E.D. Texas, case number 1:18-cv-00111. The matter is a Paragraph IV type action tied to an Abbreviated New Drug Application pathway, with patent infringement and statutory claims typical of Orange Book disputes. The docket and pleadings determine the asserted patents, the FDA product and application numbers, the filing dates, and the specific relief sought; those details are not present in the information provided, so a complete, accurate litigation and patent-strength analysis cannot be produced.
What is Adverio Pharma GmbH v. MSN Laboratories Private Limited 1:18-cv-00111 about?
Short answer: The case is a Hatch-Waxman patent infringement dispute filed by Adverio Pharma GmbH against MSN Laboratories Private Limited in the Eastern District of Texas (1:18-cv-00111).
Core dispute elements (typical for this case type)
- Infringement allegations tied to an ANDA-linked FDA submission and Orange Book-listed patents.
- Statutory claim(s) arising from a Paragraph IV certification.
- Requests for injunctive relief to prevent FDA approval or market entry, plus damages.
What drives the case outcome
- The specific Orange Book patents asserted (composition, method of use, or formulation).
- Validity and infringement defenses raised by MSN (invalidity, non-infringement, statutory exceptions).
- Procedural posture (dismissal, transfer, stay, claim construction outcome, settlement).
Which patents did Adverio Pharma assert in 1:18-cv-00111?
Short answer: Not provided in the source information.
Patent-estate analysis cannot be completed without:
- Patent numbers asserted in the complaint and any amended complaint.
- Patent assignees/holders.
- The Orange Book listing(s) tied to the asserted patents.
- Claim charts or infringement contentions.
What Orange Book patents relate to the MSN Laboratories ANDA challenged by Adverio?
Short answer: The Orange Book listing and ANDA identifiers are not provided.
What this section requires for accuracy
- Drug name and dosage form.
- Reference listed drug (RLD).
- Orange Book patent list (each patent’s expiration and type).
- Certification type(s) and listed Paragraph IV patents.
When did the lawsuit begin, and what does the timeline indicate about exclusivity risk?
Short answer: Filing year is 2018 based on the case number; the precise complaint filing date, service dates, and key docket events are not provided.
What to extract from the docket for a usable timeline
- Complaint filing date and initial asserted patents.
- Answer date, preliminary injunction motions (if any).
- Claim construction schedule and Markman hearing date.
- Summary judgment motions.
- Trial dates and any stays pending USPTO/corresponding proceedings.
- Any settlement date and dismissal date.
What procedural events matter most in 1:18-cv-00111 (Markman, stays, PTAB, or settlements)?
Short answer: Not provided in the source information.
Key outcome levers for Hatch-Waxman litigation
- Claim construction results that narrow claim scope.
- Validity findings that eliminate patent barriers.
- Stays tied to PTAB IPR/CBM proceedings.
- Settlement terms that can include licensing, launch-forfeiture, or “carve-out” windows.
How do courts typically analyze Paragraph IV infringement in cases like this?
Short answer: The typical framework is infringement then validity (and remedies), with ANDA-specific “likely to be infringed” assessments after product-specific facts are established.
Analytical components that would be populated from the pleadings
- Claim construction for the asserted independent claims.
- Infringement mapping to the proposed ANDA product.
- Materiality of any design-arounds.
- Validity contentions: novelty, obviousness, written description/enablement, indefiniteness.
What is the remedy posture: injunction, damages, or covenant-not-to-sue?
Short answer: Not provided in the source information.
What would be required for an enforceable litigation conclusion
- Whether Adverio sought a permanent injunction under 35 U.S.C. § 283.
- Whether MSN asserted invalidity/corrective prior art.
- Whether the case ended in dismissal, consent judgment, or settlement with license terms.
What does the case outcome mean for generic launch risk by MSN Laboratories?
Short answer: Not determinable without the disposition, settlement terms, or final judgment information.
Generic launch risk depends on
- Patent expiration dates for asserted patents.
- Whether any injunction issued and its scope.
- Whether a settlement includes an agreed launch date.
- Whether additional patents are still listed in Orange Book and not asserted in this action.
How strong was Adverio’s patent estate in this litigation?
Short answer: Not determinable from the provided information.
Patent-strength scoring requires
- Patent family size and remaining term as of 2018.
- Claim scope breadth (composition vs. method vs. formulations).
- Litigation history (earlier validity wins, reliance on narrow dependent claims).
- Whether the asserted patents were already challenged successfully elsewhere.
Which jurisdictions and venues are implicated beyond E.D. Texas?
Short answer: Not provided in the source information.
Typical cross-jurisdictional factors (only if they occurred)
- ITC investigations.
- PTAB proceedings (IPR/CBM).
- Parallel actions against other ANDA filers.
Adverio vs. MSN: how does this case compare to other Hatch-Waxman disputes in the same product class?
Short answer: Not possible without the drug identity and asserted patent scope.
Comparison dimensions that need product/patent facts
- Whether the case targets composition vs. method vs. formulation.
- Whether a settlement appears common for this RLD/patent cluster.
- Whether design-around strategies are typical for this target.
Key Takeaways
- Adverio Pharma GmbH v. MSN Laboratories Private Limited (1:18-cv-00111) is a Hatch-Waxman patent dispute filed in E.D. Texas in 2018.
- A precise litigation summary and patent analysis cannot be produced from the information provided because the asserted patents, product/ANDA details, docket milestones, and final disposition are not included.
- A business-grade assessment of generic launch risk, exclusivity exposure, and patent strength requires the complaint’s asserted patent numbers and the case outcome documents.
FAQs
- What is the typical claim basis for a Hatch-Waxman case numbered like 1:18-cv-00111?
- How does E.D. Texas procedure (Markman schedules) affect timelines in ANDA patent cases?
- What patent categories most often drive settlements in Paragraph IV disputes (composition vs. method vs. formulation)?
- How do PTAB IPR outcomes usually impact infringement and validity arguments in district court?
- What settlement terms most commonly determine the actual generic launch date after a Paragraph IV case?
References
No cited sources were available in the provided information.
